Literature DB >> 6610423

Serotonin-releasing effects of substituted piperazines in vitro.

D J Pettibone, M Williams.   

Abstract

The effects of various piperazine-containing compounds on the release of endogenous serotonin (5-HT) from rat hypothalamic slices were evaluated. Incubation of hypothalamic slices with m-chlorophenylpiperazine ( mCPP ) or m- trifluoromethylphenylpiperazine ( mTFMPP ) evoked a potent, dose-dependent release of endogenous 5-HT that was similar in magnitude to that seen with tryptamine, p-chloroamphetamine, or fenfluramine. In the presence of the 5-HT uptake blockers fluoxetine or chlorimipramine, this release was reduced dramatically. Furthermore, removal of calcium from the incubation medium had little effect on the drug-induced release, suggesting that the release mechanism involved displacement of 5-HT stores and not depolarization-induced exocytosis. Trazodone, MK-212, and quipazine had only small effects on release. These studies show that several piperazine-containing compounds can evoke a potent release of endogenous stores of hypothalamic 5-HT in vitro, actions which should be considered together with their direct agonist activity when interpreting the CNS effects in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610423     DOI: 10.1016/0006-2952(84)90424-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

1.  Effects of trifluoromethylphenylpiperazine (TFMPP) on interhemispheric communication.

Authors:  HeeSeung Lee; Rob R Kydd; Vanessa K Lim; Ian J Kirk; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

2.  Effect of 5-HT1A receptor agonists in two models of anxiety after dorsal raphe injection.

Authors:  G A Higgins; B J Jones; N R Oakley
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Revisiting the serotonin-aggression relation in humans: a meta-analysis.

Authors:  Aaron A Duke; Laurent Bègue; Rob Bell; Tory Eisenlohr-Moul
Journal:  Psychol Bull       Date:  2013-02-04       Impact factor: 17.737

4.  Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.

Authors:  Louise E Curley; Rob R Kydd; Michelle C Robertson; Avinesh Pillai; Nicolas McNair; HeeSeung Lee; Ian J Kirk; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2015-04-19       Impact factor: 4.530

5.  Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents.

Authors:  K Njung'e; S L Handley
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

6.  The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus.

Authors:  A M Brown; T L Patch; A J Kaumann
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

Review 7.  Pharmacology of serotonin and female sexual behavior.

Authors:  Lynda Uphouse
Journal:  Pharmacol Biochem Behav       Date:  2013-11-15       Impact factor: 3.533

8.  The influence of serotoninergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo.

Authors:  H Nissbrandt; N Waters; S Hjorth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

9.  Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo.

Authors:  C J Done; T Sharp
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

10.  Local perfusion of mCPP into ventromedial hypothalamic nucleus, but not into lateral hypothalamic area and frontal cortex, inhibits food intake in rats.

Authors:  Katsuhito Hikiji; Koki Inoue; Shinichi Iwasaki; Kyuichiro Ichihara; Nobuo Kiriike
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.